Valeant Pharmaceuticals Intl Inc.: The Plan for 2016

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) will look very different in 2016.

The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) interim CEO Howard Schiller gave his first public presentation Wednesday in San Francisco. We’ll look at the three biggest takeaways and what they mean for Valeant going forward.

1. The Walgreens deal

Valeant announced a new 20-year distribution agreement with Walgreens Boots Alliance Inc. in December, which will see many of its products sold at discounted prices.

The first phase of the program, which consists of Valeant’s dermatology products, will start on Friday. Addyi (better-known as the “female Viagra”) and ophthalmology products will follow shortly thereafter. The final phase, which consists of the Valeant drugs most exposed to generic competition, will begin in the middle of this year.

Interestingly, the Walgreens partnership will help Valeant break even this year. And while the program should become more profitable down the road, it does mark a significant shift for Valeant from years past.

2. Scaling back

Even before Wednesday Valeant had committed to shifting its strategy. Gone are the days of big acquisitions, big increases in debt, and dramatic price increases. Instead Valeant will devote the lion’s share of free cash flow–roughly US$2.25 billion–towards paying down debt.

And on Wednesday we even heard that Valeant may sell some assets. This would be a remarkable shift from Valeant’s strategy just a year ago.

It should also raise some concerns. Remember, the main argument from Valeant bears (before the current controversies surfaced) was that the company is a rollup. In other words, Valeant relies on acquisitions to cover up its fundamental problems. So once these acquisitions stop, we’ll see Valeant for what it really is.

Valeant investors better hope these bears are wrong.

3. No new updates

Valeant was facing a number of issues at the end of last year. Tops among them is what exactly happened at Philidor. There is also the big question about Michael Pearson’s health. And of course there are a litany of outside investigations into the company’s practices. Valeant provided no new updates on any of these matters, which is certainly a disappointment.

On the bright side, the company did reaffirm its guidance for this year. Those numbers were deemed very positive when originally announced, so we’ll have to wait and see if Valeant can meet them.

Without a doubt, this is a “put up or shut up” year for Valeant. So the stock will likely move very sharply as the year progresses. We’ll just have to wait and see which direction it will go.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »